(NASDAQ: GRFS) Grifols Sa's forecast annual revenue growth rate of 8.76% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.58%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.88%.
Grifols Sa's revenue in 2025 is $8,013,757,777.On average, 1 Wall Street analysts forecast GRFS's revenue for 2025 to be $6,052,195,202,121, with the lowest GRFS revenue forecast at $6,052,195,202,121, and the highest GRFS revenue forecast at $6,052,195,202,121. On average, 1 Wall Street analysts forecast GRFS's revenue for 2026 to be $6,569,174,612,995, with the lowest GRFS revenue forecast at $6,569,174,612,995, and the highest GRFS revenue forecast at $6,569,174,612,995.
In 2027, GRFS is forecast to generate $6,931,784,195,925 in revenue, with the lowest revenue forecast at $6,931,784,195,925 and the highest revenue forecast at $6,931,784,195,925.